INCMGA00012 in Combination With Chemoradiation in Participants With Stage III Non-Small Cell Lung Cancer (POD1UM-301)

Incyte logo

Incyte

Status and phase

Withdrawn
Phase 3

Conditions

Non-small Cell Lung Cancer

Treatments

Drug: Cisplatin
Drug: Etoposide
Drug: Paclitaxel
Drug: Pemetrexed
Drug: Carboplatin
Drug: Retifanlimab
Drug: Placebo
Radiation: Radiotherapy

Study type

Interventional

Funder types

Industry

Identifiers

NCT04203511
INCMGA 0012-301

Details and patient eligibility

About

The purpose of this study is to assess the efficacy and safety of INCMGA00012 in combination with chemoradiation therapy (CRT) in participants with unresectable, Stage III non-small cell lung cancer (NSCLC). The study will randomize approximately 360 participants in a 2:1 ratio into the INCMGA00012 in combination with CRT followed by consolidation therapy with INCMGA00012 treatment group and placebo in combination with CRT followed by consolidation therapy with placebo treatment group.

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Histologically or cytologically confirmed NSCLC that is locally advanced and unresectable.
  • Adequate tumor sample from fresh biopsy or archival tissue block must be available.
  • Evaluable disease per RECIST v1.1.
  • Eastern Cooperative Oncology Group performance status 0 to 1.
  • Willingness to avoid pregnancy or fathering children.

Exclusion criteria

  • Receipt of cancer treatment for this malignancy, including but not limited to radiation therapy, investigational agents, chemotherapy, and immunotherapy for disease under consideration.
  • Recent major surgery within 4 weeks before entry into the study.
  • Any medical contraindication to platinum-based doublet chemotherapy.
  • Active autoimmune disease requiring systemic immunosuppression in excess of physiologic consolidation doses of corticosteroids (> 10 mg/day of prednisone or equivalent).
  • Known hypersensitivity to another monoclonal antibody that cannot be controlled with standard measures (eg, antihistamines and corticosteroids).
  • Mixed small cell and NSCLC histology.
  • Evidence of interstitial lung disease or active noninfectious pneumonitis.
  • Participants who are HIV-positive.
  • History of organ transplant, including allogeneic stem cell transplantation.

Trial design

0 participants in 2 patient groups

Chemoradiation therapy + INCMGA00012
Experimental group
Treatment:
Radiation: Radiotherapy
Drug: Retifanlimab
Drug: Carboplatin
Drug: Paclitaxel
Drug: Pemetrexed
Drug: Etoposide
Drug: Cisplatin
Chemoradiation therapy + Placebo
Active Comparator group
Treatment:
Radiation: Radiotherapy
Drug: Placebo
Drug: Carboplatin
Drug: Paclitaxel
Drug: Pemetrexed
Drug: Etoposide
Drug: Cisplatin

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems